Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation‐Positive Non‐Small Cell Lung Cancer: A Prospective, Single‐Arm, Phase II Study

LESSONS LEARNED. The findings of this prospective, single‐arm, phase II study showed that neoadjuvant erlotinib was well tolerated and might improve the radical resection rate in patients with stage IIIA‐N2 epidermal growth factor receptor mutation‐positive non‐small cell lung cancer (NSCLC). Erloti...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Liwen, Li, Rong, Sun, Jiayuan, Lou, Yuqing, Zhang, Weiyan, Bai, Hao, Wang, Huiming, Shen, Jie, Jing, Bo, Shi, Chunlei, Zhong, Hua, Gu, Aiqin, Jiang, Liyan, Shi, Jianxing, Fang, Wentao, Zhao, Heng, Zhang, Jie, Wang, Junyuan, Ye, Junyi, Han, Baohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369937/
https://www.ncbi.nlm.nih.gov/pubmed/30158288
http://dx.doi.org/10.1634/theoncologist.2018-0120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369937/
https://www.ncbi.nlm.nih.gov/pubmed/30158288
http://dx.doi.org/10.1634/theoncologist.2018-0120

Ejemplares similares